Did Pfizer Just Say "Checkmate" to Novo Nordisk?

The weight loss drug market may approach almost $100 billion by the end of the decade.The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for weight loss, have been in high demand, and this has driven revenue of drugmaker Novo Nordisk (NVO +4.65%) higher over time.But in recent quarters, Novo has lost some ground to rival Eli Lilly, the maker of Mounjaro and Zepbound -- ...